Pharma executives tend to be circumspect when they talk about drug launches. After all, we've seen CEOs predict big things, only to be assaulted later by a pitchfork-toting mob. Plus, there's the don't-jinx-it school of thought. Apparently, neither worry applies to Novartis ($NVS) pharma chief David Epstein--at least when he's talking about the company's new heart failure drug LCZ696, which wowed folks at the European Society of Cardiology meeting over the weekend. Report